Jacobio Pharma
A clinical-stage oncology company focusing on undruggable targets.
Jacobio's pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC.
The company has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
Latest Jacobio Pharma News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze